Regulatory Approvals

The expanded label is expected to make about 5,500 additional children in the United States eligible for treatment.

BrightHeart will officially introduce the platform to European clinicians during the Fetal Medicine Foundation (FMF) World Congress in Vienna, taking place from June 28 to July 2, 2026.

The decision makes satri-cel the first CAR-T therapy anywhere in the world to receive regulatory approval for a solid tumor indication.

The ISO standard evaluates the entire diagnostic process, from sample collection to reporting, ensuring laboratories consistently produce reliable results.

The Commission argued that without the divestitures, the merged company could gain the ability to exert unilateral control over pricing in these markets.

Jascayd® acts as a selective inhibitor of phosphodiesterase-4B (PDE4B), a biological pathway linked to inflammation and fibrotic processes in the lungs.

More than 3 million cases of complicated UTIs are recorded annually in the United States, and treatment failure affects up to one-third of patients.

The EMA Committee for Orphan Medicinal Products supported the designation after recognising a strong unmet need in neuroendocrine carcinomas.

Anaphylaxis occurs when the immune system overreacts to a substance it perceives as harmful, triggering symptoms that can rapidly become life-threatening.

The approval allows the company to market the medicine across all 27 European Union member states, as well as Iceland, Liechtenstein, and Norway, subject to national pricing, reimbursement, and market-access requirements.